+612 9045 4394
 
CHECKOUT
Immunoconjugate Therapy of Hematologic Malignancies : Cancer Treatment and Research - Steven T. Rosen

Immunoconjugate Therapy of Hematologic Malignancies

Cancer Treatment and Research

By: Steven T. Rosen (Editor), Timothy M. Kuzel (Editor)

Hardcover

Published: December 2009
Ships: 7 to 10 business days
7 to 10 business days
RRP $764.99
$539.50
29%
OFF
or 4 easy payments of $134.88 with Learn more

Other Available Formats (Hide)

  • Paperback View Product Published: 25th September 2012
    $445.25

The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies. Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.

List of contributors
Introduction
Radioimmunotherapy of lymphomap. 1
High-dose radioimmunotherapy of lymphomasp. 13
Treatment of leukemia with radiolabeled monoclonal antibodiesp. 23
Imaging and dosimetry determinations using radiolabeled antibodiesp. 65
New approaches to radiolabeling monoclonal antibodiesp. 99
Immunotoxin therapy of lymphomap. 111
Immunotoxins for the therapy for graft versus host diseasep. 133
Recombinant fusion toxins - A new class of targeted biologic therapeuticsp. 145
Chimeric antibodies for the treatment of hematologic malignancyp. 161
Use of bispecific autibodies in the therapy of tumorsp. 181
Indexp. 195
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9780792322702
ISBN-10: 0792322703
Series: Cancer Treatment and Research
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 205
Published: December 2009
Publisher: Springer
Country of Publication: NL
Dimensions (cm): 23.5 x 15.5  x 1.4
Weight (kg): 1.09